200 related articles for article (PubMed ID: 37660083)
1. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.
Porter LH; Zhu JJ; Lister NL; Harrison SG; Keerthikumar S; Goode DL; Urban RQ; Byrne DJ; Azad A; Vela I; Hofman MS; Neeson PJ; Darcy PK; Trapani JA; Taylor RA; Risbridger GP
Nat Commun; 2023 Sep; 14(1):5346. PubMed ID: 37660083
[TBL] [Abstract][Full Text] [Related]
2. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
[TBL] [Abstract][Full Text] [Related]
3. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
4. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
6. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
Johnson A; Townsend M; O'Neill K
Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
[TBL] [Abstract][Full Text] [Related]
8. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
Antoñana-Vildosola A; Zanetti SR; Palazon A
Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
[TBL] [Abstract][Full Text] [Related]
9. High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.
Zurowski D; Patel S; Hui D; Ka M; Hernandez C; Love AC; Lin B; Moore A; Chan LL
SLAS Discov; 2023 Apr; 28(3):65-72. PubMed ID: 36758833
[TBL] [Abstract][Full Text] [Related]
10. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
12. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
13. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
[TBL] [Abstract][Full Text] [Related]
14. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
15. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
16. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Narayan V; Barber-Rotenberg JS; Jung IY; Lacey SF; Rech AJ; Davis MM; Hwang WT; Lal P; Carpenter EL; Maude SL; Plesa G; Vapiwala N; Chew A; Moniak M; Sebro RA; Farwell MD; Marshall A; Gilmore J; Lledo L; Dengel K; Church SE; Hether TD; Xu J; Gohil M; Buckingham TH; Yee SS; Gonzalez VE; Kulikovskaya I; Chen F; Tian L; Tien K; Gladney W; Nobles CL; Raymond HE; ; Hexner EO; Siegel DL; Bushman FD; June CH; Fraietta JA; Haas NB
Nat Med; 2022 Apr; 28(4):724-734. PubMed ID: 35314843
[TBL] [Abstract][Full Text] [Related]
17. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
18. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
19. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model.
Teng R; Zhao J; Zhao Y; Gao J; Li H; Zhou S; Wang Y; Sun Q; Lin Z; Yang W; Yin M; Wen J; Deng H
J Immunother; 2019; 42(2):33-42. PubMed ID: 30586347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
